Summit Therapeutics Inc. — Director's Dealing 2024

Oct 3, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2024-10-03

Reporting Person: Zanganeh Mahkam (Director, Co-Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-10-03	Common Stock	X	315681	$1.58	Acquired	10199776	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-10-03	Warrant (right to buy)	$1.58	X	315681	Disposed	2029-12-24	Common Stock (315681)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	25457666	Indirect
Common Stock	50000	Indirect
Common Stock	31000	Direct

Footnotes

F1: On October 3, 2024, the Shaun Zanganeh Irrevocable Trust exercised a warrant to purchase 315,681 shares of the Issuer's common stock at an exercise price of $1.58 per share.

F2: The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: Includes 489,814 shares that were previously disclosed as directly owned by the reporting person.

F4: Excludes 489,814 shares that are disclosed as indirectly owned by the reporting person through the Mahkam Zanganeh Revocable Trust.